SURG: Interesting summary on TYC. This is from TYCo's May 26th press release:
U.S. Surgical, with annual revenues of about $1.4 billion, manufactures surgical staplers, sutures, laparoscopic instrumentation, and electrosurgical products. U.S. Surgical also produces a line of advanced medical products for spinal orthopedics, vascular therapies, urology, and breast care.
This acquisition, which will increase Tyco's medical product sales to $4.5 billion, will broaden the company's disposable medical products line, especially for instruments used in and around the operating room, and should improve negotiating leverage with important purchasing organizations. In addition, the combination of U.S. Surgical with Tyco's Kendall and Sherwood-Davis & Geck businesses should offer opportunities for substantial cost savings.
I am just not as familiar with the TYC name as with USS. SURG's products are exactly what USS (now TYC) needs and I look forward to the results of the OASIS testing. As TYC's shares trade substantially higher than USS shares, and as they showed a huge amount of upward strength even during the fall of the fall, '97, I agree, this is all looking very well for SURG.
Charger |
